By Tony Fong

NEW YORK (GenomeWeb News) – Five years after its founding, and less than one year after launching its first product, molecular diagnostics firm Crescendo Bioscience is shifting to full commercialization mode for its test targeting rheumatoid arthritis.

But unlike many other startups that are transitioning from the technology development phase, the South San Francisco, Calif.-based company may not have to worry about how to provide its investors a return on its investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.